Mavenclad is a medication used to treat multiple sclerosis, and is widely prescribed to people with relapsing forms of the condition. But who makes Mavenclad, and how is it made? In this article, we’ll explore the answer to these questions, as well as the history of the medicine and its uses.
Mavenclad is a medicine manufactured by Merck & Co., Inc. It is a disease-modifying therapy for adults with relapsing-remitting multiple sclerosis, or RRMS. It is taken as two tablets, taken over a period of two days. Mavenclad works by decreasing the number of MS attacks, slowing the progression of disability, and reducing the number of lesions on MRI scans. It is available in the United States, Canada, and Europe.
Who Makes Mavenclad?
Mavenclad is an oral medication used to treat adults with relapsing multiple sclerosis (MS). The medication is manufactured and distributed by Merck KGaA, a German-based pharmaceutical and chemical company. Merck KGaA is one of the world’s oldest pharmaceutical and chemical companies, having been founded in 1668.
History of Merck KGaA
Merck KGaA was founded in 1668 in Darmstadt, Germany. It was originally a family-owned business, but in 1917 it became a public company. Merck KGaA is now a leading global healthcare company, with more than 50,000 employees in over 70 countries. In addition to prescription drugs, Merck KGaA also produces over-the-counter medications, veterinary medicines, and specialty chemicals.
Manufacturing and Distribution of Mavenclad
Merck KGaA manufactures Mavenclad at its facility in Darmstadt, Germany, and then distributes it to countries around the world. The medication is available in 10-mg and 20-mg tablets, and is usually taken twice a day. It is typically prescribed for people with relapsing multiple sclerosis (MS), although it may also be prescribed for other conditions.
Benefits of Mavenclad
Mavenclad has been shown to reduce the frequency of MS relapses in adults. In clinical trials, it has been shown to be more effective than other MS treatments, such as interferon beta-1a and glatiramer acetate. In addition, it has fewer side effects than other MS treatments, making it an attractive option for people with MS.
Related FAQ
Who Makes Mavenclad?
Answer: Mavenclad is made by Merck KGaA, a German-based multinational pharmaceutical and chemical company. Merck KGaA is one of the world’s oldest and largest pharmaceutical companies, with a long history of providing quality healthcare products. Mavenclad is approved by the European Medicines Agency and the US Food and Drug Administration for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) and is available in several countries around the world.
What is Multiple Sclerosis?
Answer: Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system. It is characterized by the destruction of the protective sheath (myelin) around nerve fibers, which can lead to a wide range of symptoms, including nerve pain, impaired vision, difficulty with balance and coordination, and fatigue.
How Does Mavenclad Work?
Answer: Mavenclad is an oral medication designed to reduce the number of relapses in people with RRMS. It works by targeting the immune cells that cause inflammation in the central nervous system. By reducing the number of inflammatory cells in the body, Mavenclad can help reduce the frequency and severity of relapses.
What are the Side Effects of Mavenclad?
Answer: Common side effects of Mavenclad include nausea, diarrhea, headache, and dizziness. Other possible side effects include hair loss, liver problems, and allergic reactions. More rare side effects include anaphylaxis, Stevens-Johnson syndrome, and angioedema. It is important to speak to your doctor if you experience any of these side effects while taking Mavenclad.
Is Mavenclad Available in the United States?
Answer: Yes, Mavenclad is available in the United States. It was approved by the US Food and Drug Administration in 2019 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). Mavenclad is available in oral tablets and can be prescribed by a doctor.
What is the Cost of Mavenclad?
Answer: The cost of Mavenclad will vary depending on your health insurance plan. However, the list price of Mavenclad is approximately $7,800 per month. Most insurance plans will cover a portion of the cost of Mavenclad, and Merck KGaA, the manufacturer of Mavenclad, offers a patient assistance program for those who are unable to afford the medication.
Mavenclad is a medication produced by Merck KGaA, a global healthcare and life science company based in Germany. It is a disease-modifying therapy that helps to reduce the frequency and severity of relapses in people with multiple sclerosis. Mavenclad is a highly effective and safe treatment option for those living with MS, and Merck KGaA is proud to be able to provide this treatment to those in need. With their commitment to advancing healthcare, Merck KGaA is dedicated to providing solutions that make a positive impact on patients’ lives.